Billerica, United States
Quanterix, headquartered in the United States, is at the forefront of revolutionizing biomarker analysis to propel the science of precision health. Founded in 2007, the company operates within the Biotechnology, Health Care, Life Sciences, and Pharmaceutical industries.
Quanterix is driven by its slogan, "Powering Biomarkers from Discovery to Diagnostics," reflecting its commitment to enhancing healthcare through ultra-sensitive detection technology, Simoa. This innovation empowers researchers to probe deeply into biomarkers, potentially transforming disease detection, prognosis, and treatment across various therapeutic fields such as oncology, neurology, cardiology, inflammation, and infectious diseases.
The company's latest significant achievement includes securing a grant on 29 March 2022 from the Alzheimer's Drug Discovery Foundation. This investment underscores the sector's faith in Quanterix's potential to deliver breakthrough advancements in precision healthcare.
